Detalles de la búsqueda
1.
Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
J Infect
; 87(1): 18-26, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37085049
2.
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Lancet Infect Dis
; 22(8): 1131-1141, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35550261
3.
Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.
J Infect
; 84(6): 795-813, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35405168
4.
Corrigendum to "Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial" [J Infect 84(6) (2022) 795-813, 5511].
J Infect
; 86(5): 540-541, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-37055303
Resultados
1 -
4
de 4
1
Próxima >
>>